Sickle Cell Disease Drug approved in EU to interfere with Pathogenesis

被引：0

|

作者：

Freye, Reimund

机构：

来源：

ACTA HAEMATOLOGICA | 2022年 / 145卷 / 05期

关键词：

BRENTUXIMAB VEDOTIN;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：573 / 573

页数：1

相关论文

共 50 条

[1] Sickle Cell Disease Drug approved in the EU to Interfere with the Pathogenesis
Freye, Reimund
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8)
[2] Sickle Cell Disease Drug to interfere with the Pathogenesis approved in the EU
Freye, Reimund
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2022, 49 (04) : 268 - 268
[3] On the pathogenesis osteosclerosis in sickle cell disease
Gilsanz, V
Kovanlikaya, A
Kaufman, F
Gribbons, D
Coates, T
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 115 - 115
[4] First Gene Therapies Approved for Sickle Cell Disease
Nelson, Roxanne
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2024, 194 (04) : e63264
[5] Amino acid product approved for sickle cell disease
Traynor, Kate
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (16) : 1206 - 1206
[6] SICKLE CELL DRUG APPROVED FOR CHILDREN AGES FOUR TO 11
Aschenbrenner, Diane S.
AMERICAN JOURNAL OF NURSING, 2022, 122 (04) : 20 - 21
[7] Mechanisms of disease - Pathogenesis and treatment of sickle cell disease
Bunn, HF
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11): : 762 - 769
[8] Impact of hemoglobin biophysical studies on molecular pathogenesis and drug therapy for sickle cell disease
Eaton, William A.
MOLECULAR ASPECTS OF MEDICINE, 2022, 84
[9] PATHOGENESIS OF LIVER LESIONS IN SICKLE CELL DISEASE
SONG, J
AMERICAN JOURNAL OF PATHOLOGY, 1970, 59 (03): : A54 - &
[10] Drug therapy for sickle cell disease
Iyamu, EW
Asakura, T
EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (06) : 807 - 813

← 1 2 3 4 5 →